Methods and compositions for inducing atherosclerotic plaque regression using colchicine

Abstract

Pharmaceutical compositions of colchicine for oral administration are provided for use in the treatment or prevention of atherosclerotic cardiovascular disease. The compositions comprise a sustained-release component, an immediate-release component, or a combination thereof, which are selectively adjustable and deliver colchicine according to a predetermined or desired release profile. The disclosed compositions and methods are designed to reduce atherosclerotic plaque, including reducing total plaque burden, and influencing plaque composition, such as non-calcified, fibrous, fibro-fatty, and calcified plaque, through targeted inhibition of vascular inflammation. In certain embodiments, administration of colchicine results in measurable changes in plaque volume and/or composition as assessed by imaging modalities, including coronary computed tomography angiography (CCTA) or intravascular ultrasound (IVUS). Methods of reducing plaque burden, altering plaque characteristics, and stabilizing vulnerable plaques, thereby lowering the risk of acute cardiovascular events in mammalian subjects, are also provided.

Dependencies are inferred from the claim text.